RNS Number : 1420O

N4 Pharma PLC

28 May 2020

28 May 2020

N4 Pharma plc

("N4 Pharma", the "Company" or the "Group")

Covid-19 Project Update

Further to the Company's announcement on 16 April 2020, N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec(R), a novel delivery system for cancer treatments and vaccines, is pleased to provide an update on the progress of its Covid-19 proof of concept work for Nuvec(R).

As previously announced, the Company appointed Evotec International Gmbh ("Evotec") to undertake the Nuvec(R) proof of concept work. The Company can confirm that the first phase of the project has been carried out, within the expected timeframe, and that the plasmid DNA has been successfully amplified to produce sufficient material for the rest of the project and has been tested to confirm it matches the required specification. Evotec has also used this batch of the plasmid DNA to express the Covid-19 spike protein to be used as a positive control for the studies. Evotec will now move to the second phase of the work and start the in-vitro testing of Nuvec(R) as planned, during the first week of June 2020. This phase is expected to last approximately ten weeks.

The third phase of the in-vivo protein expression testing will be to undertake an initial pre in-vivo study to demonstrate expression of the spike protein in target cells in a murine target. Following the recent fundraise, announced on 13 May 2020, the Company is now also exploring ways in which it can bring forward the start of certain areas of this third phase to run alongside the in-vitro work.


 N4 Pharma Plc                                  Via Scott PR 
  Nigel Theobald, CEO 
 Allenby Capital Limited             Tel: +44(0)203 328 5656 
  James Reeve/Asha Chotai 
 Turner Pope Investments (TPI) Ltd   Tel: +44(0)20 3657 0050 
  Andrew Thacker 
 Scott PR                            Tel: +44(0)1477 539 539 
  Georgia Smith 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec(R).

N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec(R) as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.



(END) Dow Jones Newswires

May 28, 2020 02:00 ET (06:00 GMT)

N4 Pharma (LSE:N4P)
Gráfica de Acción Histórica
De Jul 2020 a Ago 2020 Haga Click aquí para más Gráficas N4 Pharma.
N4 Pharma (LSE:N4P)
Gráfica de Acción Histórica
De Ago 2019 a Ago 2020 Haga Click aquí para más Gráficas N4 Pharma.